Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.
It is the long-term goal of the German CML Study Group and of the Süddeutsche Hämoblastosegruppe (SHG) to improve survival of patients with chronic myelogenous leukemia (CML). In a first randomized study (CML Study I) monotherapies with hydroxyurea or interferon alpha (IFN-alpha) were compared with a standard busulfan regimen with regard to duration of the chronic phase and survival. The main results of this study were published, 1-3 and a long-term follow up is planned. In a second randomized study the effect of the combination of IFN-alpha and hydroxyurea versus hydroxyurea monotherapy on survival is being investigated. This paper provides a first preliminary report on the study concept, patient recruitment, state of documentation and initial patients' characteristics 9 months after closure of the study.
Hehlmann
R
R
Klinikum Mannheim der Universität Heidelberg, Mannheim, Germany.
Heimpel
H
H
Hossfeld
D K
DK
Hasford
J
J
Kolb
H J
HJ
Löffler
H
H
Pralle
H
H
Queisser
W
W
Hochhaus
A
A
Tichelli
A
A
Fett
W
W
Schmitz
N
N
Reiter
A
A
Griesshammer
M
M
Pfeifer
W
W
Bümler
M
M
Kamp
T
T
Tobler
A
A
Eimermacher
H
H
Kuse
R
R
Berger
U
U
Ansari
H
H
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D005260:Female; D005858:Germany; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage*; D016898:Interferon-alpha / Q000008:administration & dosage*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000628:therapy*; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D006918:Hydroxyurea